Forest Laboratories Inc. (FRX)
-NYSE | Prev Close: | 41.84 |
|---|
| Open: | N/A |
|---|
| Bid: | 39.03 x 200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 38.38 |
|---|
| Beta: | 0.53 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 31.28 - 43.85 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,497,740 |
|---|
| Market Cap: | 11.16B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Exclusive: Forest mulls bid for Irish drugmaker Elan - sourcesReuters(Wed, Jun 19)
- Forest Laboratories one of several suitors for Elan, report saysat MarketWatch(Wed, Jun 19)
- Forest Rises On Unusually High Volume (FRX)at TheStreet(Wed, Jun 19)
- Exclusive: Forest interested in bidding for Irish drugmaker Elan - sourcesat Reuters(Wed, Jun 19)
- Eli Lilly: Cymbalta Antidepressant Sales Forecastat Seeking Alpha(Wed, Jun 19)
- Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuelat Bloomberg(Tue, Jun 18)
- 5 High Growth Healthcare Stocks With Heavy Insider Buyingat TheStreet(Tue, Jun 18)
- US Launch of Forest's Namenda XRZacks(Mon, Jun 17)
- Synergy Pharma rises as analyst starts coverageAP(Mon, Jun 17)
- Can Cempra Beat The Superbugs?at Seeking Alpha(Mon, Jun 17)
- Forest Reaches New 52-Week High (FRX)at TheStreet(Mon, Jun 17)
- Forest Laboratories Inc. (FRX): Today's Featured Health Care Winnerat TheStreet(Fri, Jun 14)
- Analysts: BlackBerry Sales Tracking Over Estimates and 3 More Research Notes to Investigateat Wall St. Cheat Sheet(Thu, Jun 13)
- Forest Announces U.S. Availability of New Once-Daily NAMENDA XRBusiness Wire(Thu, Jun 13)
- Some Dividend Stocks May Still Look Like Winnersat Seeking Alpha(Thu, Jun 13)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| FRX | 0.00% | 11.16B |
| NVO | 0.00% | 85.98B |
| TEVA | 0.00% | 33.48B |
| AGN | 0.00% | 29.43B |
Key Statistics
| Forward P/E (1 yr): | 27.89 |
|---|
| P/S (ttm): | 3.60 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 0.88 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.10 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 1.37 |
|---|
Business Summary
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic...
View More 
1.35%